SlideShare a Scribd company logo
Key Headlines
in the NHS Atlas of
Variation for
People with Liver
Disease




                      Copyright 2011 Right Care
Introducing the Atlas of Variation in Healthcare for People
    with Liver Disease

    - 38 indicators mapped
    - Covering topics ranging from
      Transplantation, alcohol, prescribing,
      and obesity, amongst other
    - Produced with NHS Liver and the
      Health Protection Agency
    - contributions from 24 other
      organisations
    - 12 case studies of innovation and
      good practice
    - With preface from three major liver
      charities
2
Preface

     [This Atlas] will highlight gaps in prevention
     initiatives and the provision of health services
     and will draw attention to localities where
     improvements are needed. Most importantly, it
     will empower patients to ask questions about
     the healthcare they receive and the options
     available to them.




3
A key issue for population health

     In the Annual Report of
     the Chief Medical Officer
     (CMO), Volume 1, 2011,
     liver disease was
     identified as one of three
     key issues for population
     health because it is:

     “the only major cause of
     mortality and morbidity
     which is on the increase
     in England...”


4
…whilst it is decreasing in our European partners




5
Mortality from liver disease has been increasing for the past 20 years.
During the last few years, it appears to have reached a plateau,
although it is not known whether this trend in mortality can be
reversed




  6
The key facts

    • 1993-2010: 88% rise in England in age-standardised mortality
      rate from chronic liver disease
    • Up to 10-20% of the population are potentially at some risk
      of developing some liver damage, while 600,000-700,000
      individuals actually have a significant degree of damage.
    • Over 24% of the population (33% of men, 16% of women)
      consume alcohol in a way that is potentially or actually
      harmful
    • In England, there are potentially 1.4m adults with fatty liver
      disease. 26% of the adult population in England is thought to
      be obese
    • Up to 500,000 children may already be at risk of liver disease
      because of their weight
7
Key Themes

      • There is significant local variation in these mortality
        rates, with deprivation a key factor. (Maps 1-5)
      • Major evidence of alcohol abuse by children, with big
        local variations in the numbers admitted to hospital for
        alcohol-related problems. (Map 10)
      • Unexplained variations in local prescribing patterns for
        people with harmful drinking (Maps 12 & 14)
      • Not all babies at risk of hepatitis B are being immunised
        to protect them. (Map 17)
      • Growing obesity in children is increasing the risk of
        serious liver disease in later life. (Maps 28-29)


8
Why Variation matters…

    Maps of variation in healthcare matter because they
    support an understanding that different resources or
    solutions may be required in different localities, but
    they also serve as a powerful tool for orientation, a
    comparator and a benchmark to show commissioners,
    clinicians and providers where they stand among their
    peers.

    Maps can help to highlight localities where variation in
    outcomes may require more detailed investigation or
    a different solution.

9
Much more needs to be done at an earlier stage of liver disease to
reduce premature mortality. Indeed, the opportunities for
intervention and the effect of intervention probably diminish with
the progression of liver disease, whereas the relative costs of the
interventions that can be applied increase




10
Selected Maps of Variation




11
Emergency Admissions

In some localities, people are twice as
likely to be admitted to hospital as an
emergency attributable to liver disease.
Reasons could include differences in:

›› the distribution of risk factors for
liver disease;
›› the prevalence of liver disease in
different populations;
›› the types and volumes of liver
disease;
›› the coding of cases.

The degree of variation observed,
however, probably includes
unwarranted variation due to
differences in the organisation and
management of care for people with
liver disease in local health services.
 12
Chronic Liver Disease

Premature death from chronic
liver disease has been rising -
between 1993 and 2010 the
directly age-standardised
mortality rate in England
increased by 88%.

There is a 9-fold variation in rates
for PCTs. When the five PCTs with
the highest rates and the five
PCTs with the lowest rates are
excluded, the variation is 3.9-fold.




 13
Sources of Variation

       Potential reasons for the degree of variation observed
       include differences in:

       ›› the prevalence of diabetes, obesity, hepatitis B and
       hepatitis C;
       ›› the level of alcohol consumption;
       ›› the level of investment in preventative measures;
       ›› the configuration of services;
       ›› the timing of diagnosis;
       ›› degree of adherence to clinical guidance;
       ›› level of patient compliance with prevention or treatment.

14
Chronic Liver Disease

Cirrhosis of the liver is an important
cause of illness and death.

In 2010, it killed more people than
were killed in transport accidents and
more women than cancer of the
cervix.

The rate of people admitted to
hospital at least once for cirrhosis
varied 3.9-fold.When the five PCTs
with the highest rates and the five
PCTs with the lowest rates are
excluded, the range is 60.7–171.6 per
100,000 population, and the variation
is 2.8-fold.



15
Liver Cancer

Around 3,900 people every year are
diagnosed with primary liver cancer
each year in the UK, which accounts
for about 1% of all cancers in the UK.

Secondary liver cancer, spreading
from elsewhere in the body, is far
more common than primary liver
cancer.

For PCTs in England, the rate of liver
cancer mortality in people aged under
75 years ranged from 0.5 to 5.3 per
100,000 population (10-fold
variation). When the 5 PCTs with the
highest rates and the 5 PCTs with the
lowest rates are excluded, the range is
0.8–3.6 per 100,000 population, and
the variation is 4.6-fold.
16
Transplantation

For PCTs in England, the rate of liver
transplants from all donors ranged
from 4.5 to 28.5 per million population
(pmp) (6-fold variation)

When the five PCTs with the highest
rates and the five PCTs with the lowest
rates are excluded, the range is 6.0–
22.5 pmp, and the variation is 3.7-fold.

Potential reasons for variation include
differences in:

›› access to local expertise in liver
disease;
›› criteria for selection for
consideration for liver transplant;
›› care pathways for people who may
require a liver transplant.
17
Alcohol Dependency

       In England, alcohol dependence affects 4% of people aged
       between 16 and 64 years (6% of men and 2% of women); over
       24% of the population (33% of men and 16% of women) consume
       alcohol in a way that is potentially or actually harmful to their
       health or well-being.

       In England, of the 1 million people aged 16–64 years who are
       alcohol dependent, only about 6% per year receive treatment:

       ›› there is often a long period between developing alcohol
       dependence and seeking help;
       ›› there is limited availability of specialist alcohol treatment
       services in some parts of the country;
       ›› alcohol misuse is under-identified by health and social care
       professionals.
18
Admissions for Alcohol Use

 Alcohol misuse costs the country around
 £21 billion a year1. In 2011, the
 Department of Health estimated the cost
 to the NHS of alcohol-related harm as
 £3.5 billion.

 The rate of alcohol-related admissions
 ranged from 1048.1 to 3557.3 per
 100,000 population (3.4-fold variation).
 When the 5 PCTs with the highest rates
 and the 5 PCTs with the variation is
 2.1-fold.

 Some of the variation is likely to be due to
 differences in alcohol use, although other
 factors such as differences in coding for
 association with alcohol could explain
 some of the variation.

1. Health Committee. Written evidence from the Department of Health (GAS
01). Annex B, paragraph 2.
http://www.publications.parliament.uk/pa/cm201213/cmselect/cmhealth/1
32/132we02.htm
  19
Admissions for Alcohol use
For PCTs in England, the rate of
alcohol-specific conditions in people
aged under 18 years ranged from 16.9
to 138.3 per 100,000 population (8-
fold variation). When the 5 PCTs with
the highest rates and the 5 PCTs with
the lowest rates are excluded, the
variation is 4.7-fold.

Much of the variation observed is likely
to be due to differences in the rate of
alcohol use. Other reasons for
variation include the level of
deprivation, which appears to have an
adverse impact, the level of obesity,
which can worsen the impact of
alcohol, demography, and coding for
association with alcohol


 20
Hepatitis and Drug Use

       People who inject drugs are at greatest risk of hepatitis C infection.
       Infections are acquired when people share contaminated injecting
       equipment.

       Ensuring people who use drugs do not contract hepatitis is one way of
       ensuring their safety and that of the local community before and during
       their recovery. Preventing transmission also has benefits for civil
       society by reducing:

       ›› harms to health;
       ›› treatment costs.

       When people who inject drugs receive treatment for their addiction, it
       provides an opportunity to undertake hepatitis C testing to identify
       new cases.

21
Hepatitis

For PCTs in England, the percentage of
hepatitis C test uptake among people who
inject drugs receiving drug treatment
ranged from 14.8% to 87.4% (6-
fold variation).

When the five PCTs with the highest
percentages and the five PCTs with the
lowest percentages are excluded, the
range is 26.5–74.2%, and the variation is
2.8-fold.

When interpreting the magnitude of
variation, it is important to note:

›› the indicator does not include people
who do not start treatment at all and/or
who are not in touch with services;
›› some people who inject drugs are very
mobile and may present to different
services at different times.
22
Hepatitis
Although hepatitis C virus is a chronic
infection, antiviral treatments are available
that will successfully clear the virus in the
majority of patients. However, unless there
is a considerable increase in people
receiving effective treatment, the future
burden of hepatitis C-related disease will
be substantial.

Admission to hospital for hepatitis C and
end-stage liver disease (ESLD) is an
outcome indicator of how successful the
identification and care of people with
hepatitis C and its prevention have been.

There is an 11 fold variation in the rate of
hospital admissions for hepatitis C-related
ESLD when the five PCTs with the highest
rates and the five PCTs with the lowest
rates are excluded.


 23
The Obesity Epidemic

        In England, there are potentially 1.4 million adults with fatty liver
        disease which may in some cases to lead to cirrhosis (non-alcoholic
        steatohepatitis) over the long term. We also estimate that there could
        be 60,000 10-year-olds with fatty liver. Extrapolating this for children
        aged 5–15 years, up to 500,000 children may already be at risk of
        developing an underlying liver disease that could lead to cirrhosis in the
        future.
     Obesity is closely related to
     the development of fatty
     liver disease, and 26% of the
     adult population, around
     14.3 million people in
     England, is thought to be
     obese


24
Obesity
For PCTs in England, the percentage
of children in school year 6 classified
as overweight or obese ranged from
24.6% to 41.8% (1.7-fold variation).

When the five PCTs with the highest
percentages and the five PCTs with
the lowest percentages are excluded,
the range is 28.8–40.3%, and the
variation is 1.4-fold.




 25
Obesity
 For PCTs in England, the
 percentage of estimated adult
 obesity ranged from 14.0% to
 30.7% (2.2-fold variation).

 When the five PCTs with the
 highest estimated
 percentages and the five PCTs
 with the lowest estimated
 percentages are excluded, the
 range is 15.6–29.0%, and the
 variation is 1.9-fold.




26
Variations in Surgery




27
Cholecystectomy
The degree of variation observed in total
rates of cholecystectomy after exclusion is
2.4-fold whereas it is 8-fold for the
percentage of elective adult day-case
laparoscopic cholecystectomy per all
elective cholecystectomies. If total rates of
cholecystectomy are considered as a proxy
for the burden of disease, it would appear
that there is less variation in the burden of
disease when compared with the variation
in the type of care given.

Further investigation is needed into the
possible causes of lower rates of day-case
surgery.

If all providers in England were to match
the day case performance of those in the
upper quartile of day-case surgery rates for
the BADS set of procedures, the estimated
annual saving could release more than £64
million.
 28
Endoscopic Retrograde
Cholangiopancreatography

ERCP is a procedure in which an
endoscope and X-rays are used to
visualise the bile duct and the
pancreatic duct. It can be used to
diagnose or treat various conditions
such as bile duct stones or pancreatic
cancer. There should be no reason
why the majority of patients
undergoing the intervention as an
elective procedure require an
overnight stay.

For PCTs in England, the variation is
28-fold. When the five PCTs with the
highest percentages and the five
PCTs with the lowest percentages are
excluded, the variation is 13-fold.

 29
Endoscopic Retrograde
Cholangiopancreatography



      The degree of variation observed in total rates of cholecystectomy after
      exclusion is 2.4-fold (see Map 31) whereas it is 8-fold for the percentage of
      elective adult
      day-case laparoscopic cholecystectomy per all elective
      cholecystectomies.

      The degree of variation observed in total rates of ERCP procedures after
      exclusion is 2.2-fold (see Map 33) whereas it is 13-fold for the percentage
      of elective ERCP procedures performed as day cases.

      If total rates of cholesystectomy and ERCP are considered as a proxy for
      the burden of disease, it would appear that there is less variation
      in the burden of disease when compared with the variation in
      the type of care given. Further investigation is needed into the
      possible causes of lower rates of day-case procedures.


 30
Reasons for variation
     The degree of variation observed in total rates of cholecystectomy
     after exclusion is 2.4-fold (see Map 31) whereas it is 8-fold for the
     percentage of elective adult day-case laparoscopic cholecystectomy
     per all elective cholecystectomies.

     The degree of variation observed in total rates of ERCP procedures
     after exclusion is 2.2-fold (see Map 33) whereas it is 13-fold for the
     percentage of elective ERCP procedures performed as day cases.

     If total rates of cholecystectomy and ERCP are considered as a proxy
     for the burden of disease, it would appear that there is less variation
     in the burden of disease when compared with the variation in
     the type of care given.

     Further investigation is needed into the possible causes of lower
     rates of day-case procedures.
31
Innovations and models of good practice in services
     While working on the National Liver Disease Strategy, many models of good
     practice and some innovations likely to be helpful in tackling unwarranted
     variation were identified (Figure CS.1). They are presented in this Atlas as
     exemplars so that commissioners, clinicians and service providers can
     consider how they may be applied in their locality.




32
Identifying liver disease earlier

     Risk assessment and early recognition of liver disease has been promoted
     by Liverpool PCT-CCG through the use of a locally enhanced service payment
     to minimise late diagnosis.

     Incentives are available to all participating primary care groups who:

         ›› identify patients at risk;
         ›› undertake relevant blood tests;
         ›› refer only those patients who meet the criteria for referral that have been
         agreed with local secondary care services – other patients are managed
         entirely in the community

     It was found that practices had different criteria and standards for referral within
     the PCT. Referral criteria and information standards were agreed with
     secondary care providers who agreed to provide a consultant-level opinion.

     Up to 40% of patients can be discharged with an advisory care plan at first
     consultation.
33
Nottingham

     A variation of this type of service model was developed in
     Nottingham where all CCG referrals from individual practices were
     centralised at a single practice.

     A two-level triage system was used, in which a general practitioner
     with an interest in gastroenterology screened referrals. In cases
     where there was uncertainty, a brief synopsis of the case was
     emailed to 1 of 5 consultant hepatologists/gastroenterologists who
     screened the scenario and made clinical recommendations.

     Of a total of 354 potential referrals screened using this system during
     one year, 75% of hepatology referrals were dealt with by giving
     advice, blood tests, recommendations and appropriate community
     management plans.



34
Alcohol abuse - Delivering brief interventions

     The introduction of alcohol liaison nurses has been recommended by
     the British Society of Gastroenterology and accepted by NHS
     Evidence as a QIPP example.

     In Nottingham, the introduction of an alcohol liaison nurse reduced
     readmission rates and drinking rates during a 12-month follow-up
     period.

     Similar models have proved effective in Bolton and Liverpool.

     In Salford, an extension of this process has been used to identify
     frequent attendees at A&E who are also known to other local
     authority agencies: a coordinated approach with key workers has
     decreased attendances and readmission rates.



35
Triage of patients to secondary care…

     In Southampton, an algorithm was developed to triage patients to no fibrosis
     (green), cirrhosis (red), or an in-between group (amber) to whom
     interventions could be targeted to impede progression of scarring disease in
     the liver.
     Three tests were used - hyaluronic acid, collagen P3 peptide, and platelet
     count
     Ten thousand people in primary care were contacted by their own GPs and
     had their alcohol intake assessed:

         ›› just over 30% were assigned to the green category of
         risk of liver disease;
         ›› just over 40% were assigned to the amber category
         of risk of liver disease;
         ›› just under 30% were assigned to the red category of
         risk of liver disease.


36
…Triage of patients to secondary care

     After assessment at one year, it was found that the initial categorisation was
     accurate with respect to not only the proportion of people assigned to each
     category of risk but also the severity of liver disease attributed to each
     individual.

     By identifying people in each category, preliminary results suggest that the
     higher the risk category identified, the greater is the impact of interventions
     aimed at reducing alcohol consumption in each group. This and other
     evidence points to the importance of individualising the information and risk
     assessment for people at risk of liver disease.




37
Patient involvement: shared decision-making…

     Involvement of patients in the decision-making process leads to higher
     satisfaction, improved outcomes, greater knowledge of their condition and
     increased adherence to treatments.

     At University Hospitals Birmingham, patients were provided with the tools to
     engage in the decision making process, including access to their own health
     records, the ability to communicate with patients who have similar conditions
     and access to appropriate healthcare resources.

     A shadow hospital IT system was created that included the electronic
     prescribing and electronic outpatient note-keeping systems, so that patients
     could view their letters, appointments and blood-test results. As well as
     being able to access their health records, patients can also communicate
     with their healthcare team and learn about their long-term condition and its
     management.



38
… Patient involvement: shared decision-making

     After successful feedback about the pilot, the system went live in July 2012
     to patients being treated within the entire liver medicine specialty and also 10
     other specialities within the Trust.

     After this initial rollout phase, there will be an external evaluation of the
     project. This is the first such project for patients with liver disease, although
     patients with kidney disease have experienced the benefits of a similar
     system, known as Renal PatientView4, for many years1.




     1.http://www.renalpatientview.org


39
www.rightcare.nhs.uk/atlas

     In print
     You can order free printed copies
     using the online form on our website

     Online
     High and Low resolution PDFs are
     available for download

     Interactive
     A fully interactive InstantAtlastm
     is available online



40
Follow Right Care online:


     - Subscribe to get a weekly digest of our blog in your inbox
     - Receive Occasional eBulletins
     - Follow us on Twitter @qipprightcare

     www.rightcare.nhs.uk




41

More Related Content

What's hot

Medicines optimisation: sharing best practices
Medicines optimisation: sharing best practicesMedicines optimisation: sharing best practices
Medicines optimisation: sharing best practices
AALForum
 
The Development of Quality Registries in Scotland: Diabetes
The Development of Quality Registries in Scotland: DiabetesThe Development of Quality Registries in Scotland: Diabetes
The Development of Quality Registries in Scotland: Diabetes
THL
 
1115 aine carroll clinical leaders forum nhc integrated care turning healthca...
1115 aine carroll clinical leaders forum nhc integrated care turning healthca...1115 aine carroll clinical leaders forum nhc integrated care turning healthca...
1115 aine carroll clinical leaders forum nhc integrated care turning healthca...
investnethealthcare
 
Improving Quality And Reducing Cost In Healthcare The Role Of Information And...
Improving Quality And Reducing Cost In Healthcare The Role Of Information And...Improving Quality And Reducing Cost In Healthcare The Role Of Information And...
Improving Quality And Reducing Cost In Healthcare The Role Of Information And...healthcareisi
 
Professor Liam Smeeth: Big Data, 30 June 2014
Professor Liam Smeeth: Big Data, 30 June 2014Professor Liam Smeeth: Big Data, 30 June 2014
Professor Liam Smeeth: Big Data, 30 June 2014
Nuffield Trust
 
The revised OECD Health Systems Performance Framework: methodological issues ...
The revised OECD Health Systems Performance Framework: methodological issues ...The revised OECD Health Systems Performance Framework: methodological issues ...
The revised OECD Health Systems Performance Framework: methodological issues ...
Sax Institute
 
Niek Klazinga | Performance reporting in OECD countries
Niek Klazinga | Performance reporting in OECD countriesNiek Klazinga | Performance reporting in OECD countries
Niek Klazinga | Performance reporting in OECD countries
Sax Institute
 
Where is the NHS now?
Where is the NHS now?Where is the NHS now?
Where is the NHS now?
The King's Fund
 
Evaluation of IC initiatives - challenges, approaches and evaluation of Engla...
Evaluation of IC initiatives - challenges, approaches and evaluation of Engla...Evaluation of IC initiatives - challenges, approaches and evaluation of Engla...
Evaluation of IC initiatives - challenges, approaches and evaluation of Engla...
Sax Institute
 
The Danish Experiences in Developing and Using National Quality Registries
The Danish Experiences in Developing and Using National Quality RegistriesThe Danish Experiences in Developing and Using National Quality Registries
The Danish Experiences in Developing and Using National Quality Registries
THL
 
Muir Gray: NHS Atlas of Variation
Muir Gray: NHS Atlas of VariationMuir Gray: NHS Atlas of Variation
Muir Gray: NHS Atlas of Variation
The King's Fund
 
YCN Breast Educational Meeting 2015-CCGs commissioning and cancer -Helen Lewis
YCN Breast Educational Meeting 2015-CCGs commissioning and cancer  -Helen LewisYCN Breast Educational Meeting 2015-CCGs commissioning and cancer  -Helen Lewis
YCN Breast Educational Meeting 2015-CCGs commissioning and cancer -Helen Lewis
Jay Naik
 
Building Equitable Patient Partnerships with EMPaCT – identifying goals and o...
Building Equitable Patient Partnerships with EMPaCT – identifying goals and o...Building Equitable Patient Partnerships with EMPaCT – identifying goals and o...
Building Equitable Patient Partnerships with EMPaCT – identifying goals and o...
Canadian Cancer Survivor Network
 
Keith Ridge - Winterbourne Medicines Programme launch
Keith Ridge - Winterbourne Medicines Programme launchKeith Ridge - Winterbourne Medicines Programme launch
Keith Ridge - Winterbourne Medicines Programme launch
NHS Improving Quality
 
Tele-Cardiology Services in the UK - Telehealth Magazine (April 2008)
Tele-Cardiology Services in the UK - Telehealth Magazine (April 2008)Tele-Cardiology Services in the UK - Telehealth Magazine (April 2008)
Tele-Cardiology Services in the UK - Telehealth Magazine (April 2008)Ofer Atzmon
 
Anna Dixon on health policy under the coalition government
Anna Dixon on health policy under the coalition governmentAnna Dixon on health policy under the coalition government
Anna Dixon on health policy under the coalition government
The King's Fund
 
ESR11 chess violeta gaveikaite poster-2
ESR11 chess violeta gaveikaite poster-2ESR11 chess violeta gaveikaite poster-2
ESR11 chess violeta gaveikaite poster-2
CHESS, Marie Sklodowska-Curie Actions, ITN - Connected Health
 
John Hennessy, Primary Care National Director, HSE
John Hennessy, Primary Care National Director, HSEJohn Hennessy, Primary Care National Director, HSE
John Hennessy, Primary Care National Director, HSE
Investnet
 
Mike Bewick: Primary care transformation: what for and why
Mike Bewick: Primary care transformation: what for and whyMike Bewick: Primary care transformation: what for and why
Mike Bewick: Primary care transformation: what for and why
The King's Fund
 
Matt Sutton: reduced mortality with hospital Pay for Performance in England
Matt Sutton: reduced mortality with hospital Pay for Performance in EnglandMatt Sutton: reduced mortality with hospital Pay for Performance in England
Matt Sutton: reduced mortality with hospital Pay for Performance in England
The King's Fund
 

What's hot (20)

Medicines optimisation: sharing best practices
Medicines optimisation: sharing best practicesMedicines optimisation: sharing best practices
Medicines optimisation: sharing best practices
 
The Development of Quality Registries in Scotland: Diabetes
The Development of Quality Registries in Scotland: DiabetesThe Development of Quality Registries in Scotland: Diabetes
The Development of Quality Registries in Scotland: Diabetes
 
1115 aine carroll clinical leaders forum nhc integrated care turning healthca...
1115 aine carroll clinical leaders forum nhc integrated care turning healthca...1115 aine carroll clinical leaders forum nhc integrated care turning healthca...
1115 aine carroll clinical leaders forum nhc integrated care turning healthca...
 
Improving Quality And Reducing Cost In Healthcare The Role Of Information And...
Improving Quality And Reducing Cost In Healthcare The Role Of Information And...Improving Quality And Reducing Cost In Healthcare The Role Of Information And...
Improving Quality And Reducing Cost In Healthcare The Role Of Information And...
 
Professor Liam Smeeth: Big Data, 30 June 2014
Professor Liam Smeeth: Big Data, 30 June 2014Professor Liam Smeeth: Big Data, 30 June 2014
Professor Liam Smeeth: Big Data, 30 June 2014
 
The revised OECD Health Systems Performance Framework: methodological issues ...
The revised OECD Health Systems Performance Framework: methodological issues ...The revised OECD Health Systems Performance Framework: methodological issues ...
The revised OECD Health Systems Performance Framework: methodological issues ...
 
Niek Klazinga | Performance reporting in OECD countries
Niek Klazinga | Performance reporting in OECD countriesNiek Klazinga | Performance reporting in OECD countries
Niek Klazinga | Performance reporting in OECD countries
 
Where is the NHS now?
Where is the NHS now?Where is the NHS now?
Where is the NHS now?
 
Evaluation of IC initiatives - challenges, approaches and evaluation of Engla...
Evaluation of IC initiatives - challenges, approaches and evaluation of Engla...Evaluation of IC initiatives - challenges, approaches and evaluation of Engla...
Evaluation of IC initiatives - challenges, approaches and evaluation of Engla...
 
The Danish Experiences in Developing and Using National Quality Registries
The Danish Experiences in Developing and Using National Quality RegistriesThe Danish Experiences in Developing and Using National Quality Registries
The Danish Experiences in Developing and Using National Quality Registries
 
Muir Gray: NHS Atlas of Variation
Muir Gray: NHS Atlas of VariationMuir Gray: NHS Atlas of Variation
Muir Gray: NHS Atlas of Variation
 
YCN Breast Educational Meeting 2015-CCGs commissioning and cancer -Helen Lewis
YCN Breast Educational Meeting 2015-CCGs commissioning and cancer  -Helen LewisYCN Breast Educational Meeting 2015-CCGs commissioning and cancer  -Helen Lewis
YCN Breast Educational Meeting 2015-CCGs commissioning and cancer -Helen Lewis
 
Building Equitable Patient Partnerships with EMPaCT – identifying goals and o...
Building Equitable Patient Partnerships with EMPaCT – identifying goals and o...Building Equitable Patient Partnerships with EMPaCT – identifying goals and o...
Building Equitable Patient Partnerships with EMPaCT – identifying goals and o...
 
Keith Ridge - Winterbourne Medicines Programme launch
Keith Ridge - Winterbourne Medicines Programme launchKeith Ridge - Winterbourne Medicines Programme launch
Keith Ridge - Winterbourne Medicines Programme launch
 
Tele-Cardiology Services in the UK - Telehealth Magazine (April 2008)
Tele-Cardiology Services in the UK - Telehealth Magazine (April 2008)Tele-Cardiology Services in the UK - Telehealth Magazine (April 2008)
Tele-Cardiology Services in the UK - Telehealth Magazine (April 2008)
 
Anna Dixon on health policy under the coalition government
Anna Dixon on health policy under the coalition governmentAnna Dixon on health policy under the coalition government
Anna Dixon on health policy under the coalition government
 
ESR11 chess violeta gaveikaite poster-2
ESR11 chess violeta gaveikaite poster-2ESR11 chess violeta gaveikaite poster-2
ESR11 chess violeta gaveikaite poster-2
 
John Hennessy, Primary Care National Director, HSE
John Hennessy, Primary Care National Director, HSEJohn Hennessy, Primary Care National Director, HSE
John Hennessy, Primary Care National Director, HSE
 
Mike Bewick: Primary care transformation: what for and why
Mike Bewick: Primary care transformation: what for and whyMike Bewick: Primary care transformation: what for and why
Mike Bewick: Primary care transformation: what for and why
 
Matt Sutton: reduced mortality with hospital Pay for Performance in England
Matt Sutton: reduced mortality with hospital Pay for Performance in EnglandMatt Sutton: reduced mortality with hospital Pay for Performance in England
Matt Sutton: reduced mortality with hospital Pay for Performance in England
 

Viewers also liked

Alcoholic liver disease by dr. sundar karki
Alcoholic liver disease  by dr. sundar karkiAlcoholic liver disease  by dr. sundar karki
Alcoholic liver disease by dr. sundar karki
Dr. Sundar Karki
 
Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-Alcoholic Fatty Liver Disease (NAFLD)Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-Alcoholic Fatty Liver Disease (NAFLD)
Sariu Ali
 
Healthcare Industry India Overview and City Comparison
Healthcare Industry India Overview and City ComparisonHealthcare Industry India Overview and City Comparison
Healthcare Industry India Overview and City Comparison
Sanket Baxi
 
Adrenal mets ct
Adrenal mets   ctAdrenal mets   ct
Adrenal mets ct
Udayamoorthy Kasirajan
 
Indiana University Health University Hospital Palliative Care Services
Indiana University Health University Hospital Palliative Care ServicesIndiana University Health University Hospital Palliative Care Services
Indiana University Health University Hospital Palliative Care Services
Mike Aref
 
Alternative health system and public private partnership
Alternative health system and public private partnershipAlternative health system and public private partnership
Alternative health system and public private partnershipNursing Path
 
MCO 2011 - Slide 24 - G.J. Poston - Spotlight session - Targeted therapies in...
MCO 2011 - Slide 24 - G.J. Poston - Spotlight session - Targeted therapies in...MCO 2011 - Slide 24 - G.J. Poston - Spotlight session - Targeted therapies in...
MCO 2011 - Slide 24 - G.J. Poston - Spotlight session - Targeted therapies in...European School of Oncology
 
CHEMOTHERAPY PREPARATION AND STABILITY CHART
CHEMOTHERAPY PREPARATION AND STABILITY CHARTCHEMOTHERAPY PREPARATION AND STABILITY CHART
CHEMOTHERAPY PREPARATION AND STABILITY CHART
Clinica de imagenes
 
Dr-Ali Alseyani Case persentation
Dr-Ali Alseyani Case persentationDr-Ali Alseyani Case persentation
Dr-Ali Alseyani Case persentation
Royal medical services - JOS
 
Chronic Liver Disease in pediatric: a case presentation and discussion
Chronic Liver Disease in pediatric: a case presentation and discussionChronic Liver Disease in pediatric: a case presentation and discussion
Chronic Liver Disease in pediatric: a case presentation and discussion
Dr Abdalla M. Gamal
 
Hepatitis A, B, and C its management and treatment
Hepatitis A, B, and C its management and treatmentHepatitis A, B, and C its management and treatment
Hepatitis A, B, and C its management and treatment
Jack Frost
 
Approach to liver disease
Approach to liver diseaseApproach to liver disease
Approach to liver diseaseanoop r prasad
 
chronic liver disease
chronic liver diseasechronic liver disease
chronic liver diseasessn zhd
 
19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosisinternalmed
 
Nonalcoholic fatty liver disease
Nonalcoholic fatty liver diseaseNonalcoholic fatty liver disease
Nonalcoholic fatty liver diseaseAshish Kumar
 

Viewers also liked (16)

Alcoholic liver disease by dr. sundar karki
Alcoholic liver disease  by dr. sundar karkiAlcoholic liver disease  by dr. sundar karki
Alcoholic liver disease by dr. sundar karki
 
Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-Alcoholic Fatty Liver Disease (NAFLD)Non-Alcoholic Fatty Liver Disease (NAFLD)
Non-Alcoholic Fatty Liver Disease (NAFLD)
 
Healthcare Industry India Overview and City Comparison
Healthcare Industry India Overview and City ComparisonHealthcare Industry India Overview and City Comparison
Healthcare Industry India Overview and City Comparison
 
Adrenal mets ct
Adrenal mets   ctAdrenal mets   ct
Adrenal mets ct
 
Indiana University Health University Hospital Palliative Care Services
Indiana University Health University Hospital Palliative Care ServicesIndiana University Health University Hospital Palliative Care Services
Indiana University Health University Hospital Palliative Care Services
 
Alternative health system and public private partnership
Alternative health system and public private partnershipAlternative health system and public private partnership
Alternative health system and public private partnership
 
MCO 2011 - Slide 24 - G.J. Poston - Spotlight session - Targeted therapies in...
MCO 2011 - Slide 24 - G.J. Poston - Spotlight session - Targeted therapies in...MCO 2011 - Slide 24 - G.J. Poston - Spotlight session - Targeted therapies in...
MCO 2011 - Slide 24 - G.J. Poston - Spotlight session - Targeted therapies in...
 
CHEMOTHERAPY PREPARATION AND STABILITY CHART
CHEMOTHERAPY PREPARATION AND STABILITY CHARTCHEMOTHERAPY PREPARATION AND STABILITY CHART
CHEMOTHERAPY PREPARATION AND STABILITY CHART
 
Dr-Ali Alseyani Case persentation
Dr-Ali Alseyani Case persentationDr-Ali Alseyani Case persentation
Dr-Ali Alseyani Case persentation
 
Chronic Liver Disease in pediatric: a case presentation and discussion
Chronic Liver Disease in pediatric: a case presentation and discussionChronic Liver Disease in pediatric: a case presentation and discussion
Chronic Liver Disease in pediatric: a case presentation and discussion
 
Hepatitis A, B, and C its management and treatment
Hepatitis A, B, and C its management and treatmentHepatitis A, B, and C its management and treatment
Hepatitis A, B, and C its management and treatment
 
Approach to liver disease
Approach to liver diseaseApproach to liver disease
Approach to liver disease
 
chronic liver disease
chronic liver diseasechronic liver disease
chronic liver disease
 
Liver Disease
Liver DiseaseLiver Disease
Liver Disease
 
19 hepatic cirrhosis
19 hepatic cirrhosis19 hepatic cirrhosis
19 hepatic cirrhosis
 
Nonalcoholic fatty liver disease
Nonalcoholic fatty liver diseaseNonalcoholic fatty liver disease
Nonalcoholic fatty liver disease
 

Similar to NHS Atlas of Variation in Healthcare for People with Liver Disease

Diabetes atlas key headlines 2012
Diabetes atlas   key headlines 2012Diabetes atlas   key headlines 2012
Diabetes atlas key headlines 2012rightcare
 
B743SG - The Social Context of Health Care Provision and Delivery - Coronary...
B743SG - The Social Context of Health Care Provision and Delivery -  Coronary...B743SG - The Social Context of Health Care Provision and Delivery -  Coronary...
B743SG - The Social Context of Health Care Provision and Delivery - Coronary...Mike Dunn
 
Chronic kidney diseases and its causes and trends in global and Bangladesh p...
Chronic kidney diseases and its causes and  trends in global and Bangladesh p...Chronic kidney diseases and its causes and  trends in global and Bangladesh p...
Chronic kidney diseases and its causes and trends in global and Bangladesh p...
BSMMU
 
HannoverRe_InFocus68_CKD_Dec2015
HannoverRe_InFocus68_CKD_Dec2015HannoverRe_InFocus68_CKD_Dec2015
HannoverRe_InFocus68_CKD_Dec2015Paul Edwards
 
Coronary heart disease
Coronary heart diseaseCoronary heart disease
Coronary heart disease
drsanjeev15
 
Death from liver disease : Implications for end of life care in England
Death from liver disease : Implications for end of life care in EnglandDeath from liver disease : Implications for end of life care in England
Death from liver disease : Implications for end of life care in England
NHS IQ legacy organisations
 
Getting to grips with Population Health - 28th Feb 2018
Getting to grips with Population Health - 28th Feb 2018Getting to grips with Population Health - 28th Feb 2018
Getting to grips with Population Health - 28th Feb 2018
James Carter
 
Jgh3 4-351
Jgh3 4-351Jgh3 4-351
Jgh3 4-351
rakeshsrivastava89
 
2019 AHA Hypertension Management in Older and Frail Older Patients.pdf
2019 AHA Hypertension Management in Older and Frail Older Patients.pdf2019 AHA Hypertension Management in Older and Frail Older Patients.pdf
2019 AHA Hypertension Management in Older and Frail Older Patients.pdf
karimahkhitamiaziz1
 
Diet, nutrition and the prevention of cancer,ppt
Diet, nutrition and the prevention of cancer,pptDiet, nutrition and the prevention of cancer,ppt
Diet, nutrition and the prevention of cancer,pptRajeeeeeeeeeeev
 
Lancet liver disease infographic
Lancet liver disease infographicLancet liver disease infographic
Lancet liver disease infographic
Aimée Stewart
 
Smoking & liver
Smoking & liverSmoking & liver
Smoking & liver
Ashraf ElAdawy
 
noncommunicablediseasespro1-180101054815.pdf
noncommunicablediseasespro1-180101054815.pdfnoncommunicablediseasespro1-180101054815.pdf
noncommunicablediseasespro1-180101054815.pdf
KristineHP
 
Increasing Burden of NCD in Malaysia: Challenges in resource allocation
Increasing Burden of NCD in Malaysia: Challenges in resource allocationIncreasing Burden of NCD in Malaysia: Challenges in resource allocation
Increasing Burden of NCD in Malaysia: Challenges in resource allocation
Feisul Mustapha
 
The use of mobile solutions in cardiovascular disease trials
The use of mobile solutions in cardiovascular disease trials The use of mobile solutions in cardiovascular disease trials
The use of mobile solutions in cardiovascular disease trials
Vikrant Patnaik
 
Epidemiology of Non Communicable Diseases (NCDs)
Epidemiology of Non Communicable Diseases (NCDs)Epidemiology of Non Communicable Diseases (NCDs)
Epidemiology of Non Communicable Diseases (NCDs)
Prabesh Ghimire
 
Srivastava Rakesh cells Research paper
 Srivastava Rakesh  cells  Research paper Srivastava Rakesh  cells  Research paper
Srivastava Rakesh cells Research paper
RakeshSrivastava87
 
Burden of liver disease progression in hospitalized patients JOURNAL 2.pptx
Burden of liver disease progression in hospitalized patients JOURNAL 2.pptxBurden of liver disease progression in hospitalized patients JOURNAL 2.pptx
Burden of liver disease progression in hospitalized patients JOURNAL 2.pptx
DrHarsh Saxena
 
Risk factors of cardiovascular
Risk factors of cardiovascularRisk factors of cardiovascular
Risk factors of cardiovascularDr Vaibhav Gupta
 

Similar to NHS Atlas of Variation in Healthcare for People with Liver Disease (20)

Diabetes atlas key headlines 2012
Diabetes atlas   key headlines 2012Diabetes atlas   key headlines 2012
Diabetes atlas key headlines 2012
 
B743SG - The Social Context of Health Care Provision and Delivery - Coronary...
B743SG - The Social Context of Health Care Provision and Delivery -  Coronary...B743SG - The Social Context of Health Care Provision and Delivery -  Coronary...
B743SG - The Social Context of Health Care Provision and Delivery - Coronary...
 
Chronic kidney diseases and its causes and trends in global and Bangladesh p...
Chronic kidney diseases and its causes and  trends in global and Bangladesh p...Chronic kidney diseases and its causes and  trends in global and Bangladesh p...
Chronic kidney diseases and its causes and trends in global and Bangladesh p...
 
HannoverRe_InFocus68_CKD_Dec2015
HannoverRe_InFocus68_CKD_Dec2015HannoverRe_InFocus68_CKD_Dec2015
HannoverRe_InFocus68_CKD_Dec2015
 
Coronary heart disease
Coronary heart diseaseCoronary heart disease
Coronary heart disease
 
Death from liver disease : Implications for end of life care in England
Death from liver disease : Implications for end of life care in EnglandDeath from liver disease : Implications for end of life care in England
Death from liver disease : Implications for end of life care in England
 
Getting to grips with Population Health - 28th Feb 2018
Getting to grips with Population Health - 28th Feb 2018Getting to grips with Population Health - 28th Feb 2018
Getting to grips with Population Health - 28th Feb 2018
 
Jgh3 4-351
Jgh3 4-351Jgh3 4-351
Jgh3 4-351
 
2019 AHA Hypertension Management in Older and Frail Older Patients.pdf
2019 AHA Hypertension Management in Older and Frail Older Patients.pdf2019 AHA Hypertension Management in Older and Frail Older Patients.pdf
2019 AHA Hypertension Management in Older and Frail Older Patients.pdf
 
Diet, nutrition and the prevention of cancer,ppt
Diet, nutrition and the prevention of cancer,pptDiet, nutrition and the prevention of cancer,ppt
Diet, nutrition and the prevention of cancer,ppt
 
Lancet liver disease infographic
Lancet liver disease infographicLancet liver disease infographic
Lancet liver disease infographic
 
Smoking & liver
Smoking & liverSmoking & liver
Smoking & liver
 
noncommunicablediseasespro1-180101054815.pdf
noncommunicablediseasespro1-180101054815.pdfnoncommunicablediseasespro1-180101054815.pdf
noncommunicablediseasespro1-180101054815.pdf
 
Increasing Burden of NCD in Malaysia: Challenges in resource allocation
Increasing Burden of NCD in Malaysia: Challenges in resource allocationIncreasing Burden of NCD in Malaysia: Challenges in resource allocation
Increasing Burden of NCD in Malaysia: Challenges in resource allocation
 
The use of mobile solutions in cardiovascular disease trials
The use of mobile solutions in cardiovascular disease trials The use of mobile solutions in cardiovascular disease trials
The use of mobile solutions in cardiovascular disease trials
 
CVD 15
CVD 15CVD 15
CVD 15
 
Epidemiology of Non Communicable Diseases (NCDs)
Epidemiology of Non Communicable Diseases (NCDs)Epidemiology of Non Communicable Diseases (NCDs)
Epidemiology of Non Communicable Diseases (NCDs)
 
Srivastava Rakesh cells Research paper
 Srivastava Rakesh  cells  Research paper Srivastava Rakesh  cells  Research paper
Srivastava Rakesh cells Research paper
 
Burden of liver disease progression in hospitalized patients JOURNAL 2.pptx
Burden of liver disease progression in hospitalized patients JOURNAL 2.pptxBurden of liver disease progression in hospitalized patients JOURNAL 2.pptx
Burden of liver disease progression in hospitalized patients JOURNAL 2.pptx
 
Risk factors of cardiovascular
Risk factors of cardiovascularRisk factors of cardiovascular
Risk factors of cardiovascular
 

More from rightcare

An Overview of the Right Care philosopy and approach
An Overview of the Right Care philosopy and approachAn Overview of the Right Care philosopy and approach
An Overview of the Right Care philosopy and approachrightcare
 
Diagnostic services atlas key headlines nov 2013 -v1
Diagnostic services  atlas   key headlines nov 2013 -v1Diagnostic services  atlas   key headlines nov 2013 -v1
Diagnostic services atlas key headlines nov 2013 -v1rightcare
 
The need to understand variation in healthcare population healthcare online...
The need to understand variation in healthcare   population healthcare online...The need to understand variation in healthcare   population healthcare online...
The need to understand variation in healthcare population healthcare online...
rightcare
 
Introduction why act - Right Care for Populations - online learning
Introduction   why act - Right Care for Populations -  online learningIntroduction   why act - Right Care for Populations -  online learning
Introduction why act - Right Care for Populations - online learning
rightcare
 
A new tool for Clinical Commissioners, HWBs and everyone concerned with commi...
A new tool for Clinical Commissioners, HWBs and everyone concerned with commi...A new tool for Clinical Commissioners, HWBs and everyone concerned with commi...
A new tool for Clinical Commissioners, HWBs and everyone concerned with commi...
rightcare
 
Right Care @ the NaPC Conference
Right Care @ the NaPC ConferenceRight Care @ the NaPC Conference
Right Care @ the NaPC Conference
rightcare
 
Right Care Atlas of Variation in Healthcare - Children and Young People
Right Care Atlas of Variation in Healthcare - Children and Young PeopleRight Care Atlas of Variation in Healthcare - Children and Young People
Right Care Atlas of Variation in Healthcare - Children and Young People
rightcare
 
Right care sdm_launch_presentation_sept_2011
Right care sdm_launch_presentation_sept_2011Right care sdm_launch_presentation_sept_2011
Right care sdm_launch_presentation_sept_2011rightcare
 

More from rightcare (8)

An Overview of the Right Care philosopy and approach
An Overview of the Right Care philosopy and approachAn Overview of the Right Care philosopy and approach
An Overview of the Right Care philosopy and approach
 
Diagnostic services atlas key headlines nov 2013 -v1
Diagnostic services  atlas   key headlines nov 2013 -v1Diagnostic services  atlas   key headlines nov 2013 -v1
Diagnostic services atlas key headlines nov 2013 -v1
 
The need to understand variation in healthcare population healthcare online...
The need to understand variation in healthcare   population healthcare online...The need to understand variation in healthcare   population healthcare online...
The need to understand variation in healthcare population healthcare online...
 
Introduction why act - Right Care for Populations - online learning
Introduction   why act - Right Care for Populations -  online learningIntroduction   why act - Right Care for Populations -  online learning
Introduction why act - Right Care for Populations - online learning
 
A new tool for Clinical Commissioners, HWBs and everyone concerned with commi...
A new tool for Clinical Commissioners, HWBs and everyone concerned with commi...A new tool for Clinical Commissioners, HWBs and everyone concerned with commi...
A new tool for Clinical Commissioners, HWBs and everyone concerned with commi...
 
Right Care @ the NaPC Conference
Right Care @ the NaPC ConferenceRight Care @ the NaPC Conference
Right Care @ the NaPC Conference
 
Right Care Atlas of Variation in Healthcare - Children and Young People
Right Care Atlas of Variation in Healthcare - Children and Young PeopleRight Care Atlas of Variation in Healthcare - Children and Young People
Right Care Atlas of Variation in Healthcare - Children and Young People
 
Right care sdm_launch_presentation_sept_2011
Right care sdm_launch_presentation_sept_2011Right care sdm_launch_presentation_sept_2011
Right care sdm_launch_presentation_sept_2011
 

Recently uploaded

Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
pal078100
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
Swetaba Besh
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
Sapna Thakur
 
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
chandankumarsmartiso
 
planning for change nursing Management ppt
planning for change nursing Management pptplanning for change nursing Management ppt
planning for change nursing Management ppt
Thangamjayarani
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
Dr. Vinay Pareek
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
KafrELShiekh University
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
kevinkariuki227
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
Shweta
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Prof. Marcus Renato de Carvalho
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 

Recently uploaded (20)

Ocular injury ppt Upendra pal optometrist upums saifai etawah
Ocular injury  ppt  Upendra pal  optometrist upums saifai etawahOcular injury  ppt  Upendra pal  optometrist upums saifai etawah
Ocular injury ppt Upendra pal optometrist upums saifai etawah
 
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptxANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
ANATOMY AND PHYSIOLOGY OF URINARY SYSTEM.pptx
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
NVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control programNVBDCP.pptx Nation vector borne disease control program
NVBDCP.pptx Nation vector borne disease control program
 
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in DehradunDehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
Dehradun #ℂall #gIRLS Oyo Hotel 9719300533 #ℂall #gIRL in Dehradun
 
planning for change nursing Management ppt
planning for change nursing Management pptplanning for change nursing Management ppt
planning for change nursing Management ppt
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTSARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS
 
Ophthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE examOphthalmology Clinical Tests for OSCE exam
Ophthalmology Clinical Tests for OSCE exam
 
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
 
Evaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animalsEvaluation of antidepressant activity of clitoris ternatea in animals
Evaluation of antidepressant activity of clitoris ternatea in animals
 
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidadeNovas diretrizes da OMS para os cuidados perinatais de mais qualidade
Novas diretrizes da OMS para os cuidados perinatais de mais qualidade
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptxTriangles of Neck and Clinical Correlation by Dr. RIG.pptx
Triangles of Neck and Clinical Correlation by Dr. RIG.pptx
 
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptxThyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
Thyroid Gland- Gross Anatomy by Dr. Rabia Inam Gandapore.pptx
 

NHS Atlas of Variation in Healthcare for People with Liver Disease

  • 1. Key Headlines in the NHS Atlas of Variation for People with Liver Disease Copyright 2011 Right Care
  • 2. Introducing the Atlas of Variation in Healthcare for People with Liver Disease - 38 indicators mapped - Covering topics ranging from Transplantation, alcohol, prescribing, and obesity, amongst other - Produced with NHS Liver and the Health Protection Agency - contributions from 24 other organisations - 12 case studies of innovation and good practice - With preface from three major liver charities 2
  • 3. Preface [This Atlas] will highlight gaps in prevention initiatives and the provision of health services and will draw attention to localities where improvements are needed. Most importantly, it will empower patients to ask questions about the healthcare they receive and the options available to them. 3
  • 4. A key issue for population health In the Annual Report of the Chief Medical Officer (CMO), Volume 1, 2011, liver disease was identified as one of three key issues for population health because it is: “the only major cause of mortality and morbidity which is on the increase in England...” 4
  • 5. …whilst it is decreasing in our European partners 5
  • 6. Mortality from liver disease has been increasing for the past 20 years. During the last few years, it appears to have reached a plateau, although it is not known whether this trend in mortality can be reversed 6
  • 7. The key facts • 1993-2010: 88% rise in England in age-standardised mortality rate from chronic liver disease • Up to 10-20% of the population are potentially at some risk of developing some liver damage, while 600,000-700,000 individuals actually have a significant degree of damage. • Over 24% of the population (33% of men, 16% of women) consume alcohol in a way that is potentially or actually harmful • In England, there are potentially 1.4m adults with fatty liver disease. 26% of the adult population in England is thought to be obese • Up to 500,000 children may already be at risk of liver disease because of their weight 7
  • 8. Key Themes • There is significant local variation in these mortality rates, with deprivation a key factor. (Maps 1-5) • Major evidence of alcohol abuse by children, with big local variations in the numbers admitted to hospital for alcohol-related problems. (Map 10) • Unexplained variations in local prescribing patterns for people with harmful drinking (Maps 12 & 14) • Not all babies at risk of hepatitis B are being immunised to protect them. (Map 17) • Growing obesity in children is increasing the risk of serious liver disease in later life. (Maps 28-29) 8
  • 9. Why Variation matters… Maps of variation in healthcare matter because they support an understanding that different resources or solutions may be required in different localities, but they also serve as a powerful tool for orientation, a comparator and a benchmark to show commissioners, clinicians and providers where they stand among their peers. Maps can help to highlight localities where variation in outcomes may require more detailed investigation or a different solution. 9
  • 10. Much more needs to be done at an earlier stage of liver disease to reduce premature mortality. Indeed, the opportunities for intervention and the effect of intervention probably diminish with the progression of liver disease, whereas the relative costs of the interventions that can be applied increase 10
  • 11. Selected Maps of Variation 11
  • 12. Emergency Admissions In some localities, people are twice as likely to be admitted to hospital as an emergency attributable to liver disease. Reasons could include differences in: ›› the distribution of risk factors for liver disease; ›› the prevalence of liver disease in different populations; ›› the types and volumes of liver disease; ›› the coding of cases. The degree of variation observed, however, probably includes unwarranted variation due to differences in the organisation and management of care for people with liver disease in local health services. 12
  • 13. Chronic Liver Disease Premature death from chronic liver disease has been rising - between 1993 and 2010 the directly age-standardised mortality rate in England increased by 88%. There is a 9-fold variation in rates for PCTs. When the five PCTs with the highest rates and the five PCTs with the lowest rates are excluded, the variation is 3.9-fold. 13
  • 14. Sources of Variation Potential reasons for the degree of variation observed include differences in: ›› the prevalence of diabetes, obesity, hepatitis B and hepatitis C; ›› the level of alcohol consumption; ›› the level of investment in preventative measures; ›› the configuration of services; ›› the timing of diagnosis; ›› degree of adherence to clinical guidance; ›› level of patient compliance with prevention or treatment. 14
  • 15. Chronic Liver Disease Cirrhosis of the liver is an important cause of illness and death. In 2010, it killed more people than were killed in transport accidents and more women than cancer of the cervix. The rate of people admitted to hospital at least once for cirrhosis varied 3.9-fold.When the five PCTs with the highest rates and the five PCTs with the lowest rates are excluded, the range is 60.7–171.6 per 100,000 population, and the variation is 2.8-fold. 15
  • 16. Liver Cancer Around 3,900 people every year are diagnosed with primary liver cancer each year in the UK, which accounts for about 1% of all cancers in the UK. Secondary liver cancer, spreading from elsewhere in the body, is far more common than primary liver cancer. For PCTs in England, the rate of liver cancer mortality in people aged under 75 years ranged from 0.5 to 5.3 per 100,000 population (10-fold variation). When the 5 PCTs with the highest rates and the 5 PCTs with the lowest rates are excluded, the range is 0.8–3.6 per 100,000 population, and the variation is 4.6-fold. 16
  • 17. Transplantation For PCTs in England, the rate of liver transplants from all donors ranged from 4.5 to 28.5 per million population (pmp) (6-fold variation) When the five PCTs with the highest rates and the five PCTs with the lowest rates are excluded, the range is 6.0– 22.5 pmp, and the variation is 3.7-fold. Potential reasons for variation include differences in: ›› access to local expertise in liver disease; ›› criteria for selection for consideration for liver transplant; ›› care pathways for people who may require a liver transplant. 17
  • 18. Alcohol Dependency In England, alcohol dependence affects 4% of people aged between 16 and 64 years (6% of men and 2% of women); over 24% of the population (33% of men and 16% of women) consume alcohol in a way that is potentially or actually harmful to their health or well-being. In England, of the 1 million people aged 16–64 years who are alcohol dependent, only about 6% per year receive treatment: ›› there is often a long period between developing alcohol dependence and seeking help; ›› there is limited availability of specialist alcohol treatment services in some parts of the country; ›› alcohol misuse is under-identified by health and social care professionals. 18
  • 19. Admissions for Alcohol Use Alcohol misuse costs the country around £21 billion a year1. In 2011, the Department of Health estimated the cost to the NHS of alcohol-related harm as £3.5 billion. The rate of alcohol-related admissions ranged from 1048.1 to 3557.3 per 100,000 population (3.4-fold variation). When the 5 PCTs with the highest rates and the 5 PCTs with the variation is 2.1-fold. Some of the variation is likely to be due to differences in alcohol use, although other factors such as differences in coding for association with alcohol could explain some of the variation. 1. Health Committee. Written evidence from the Department of Health (GAS 01). Annex B, paragraph 2. http://www.publications.parliament.uk/pa/cm201213/cmselect/cmhealth/1 32/132we02.htm 19
  • 20. Admissions for Alcohol use For PCTs in England, the rate of alcohol-specific conditions in people aged under 18 years ranged from 16.9 to 138.3 per 100,000 population (8- fold variation). When the 5 PCTs with the highest rates and the 5 PCTs with the lowest rates are excluded, the variation is 4.7-fold. Much of the variation observed is likely to be due to differences in the rate of alcohol use. Other reasons for variation include the level of deprivation, which appears to have an adverse impact, the level of obesity, which can worsen the impact of alcohol, demography, and coding for association with alcohol 20
  • 21. Hepatitis and Drug Use People who inject drugs are at greatest risk of hepatitis C infection. Infections are acquired when people share contaminated injecting equipment. Ensuring people who use drugs do not contract hepatitis is one way of ensuring their safety and that of the local community before and during their recovery. Preventing transmission also has benefits for civil society by reducing: ›› harms to health; ›› treatment costs. When people who inject drugs receive treatment for their addiction, it provides an opportunity to undertake hepatitis C testing to identify new cases. 21
  • 22. Hepatitis For PCTs in England, the percentage of hepatitis C test uptake among people who inject drugs receiving drug treatment ranged from 14.8% to 87.4% (6- fold variation). When the five PCTs with the highest percentages and the five PCTs with the lowest percentages are excluded, the range is 26.5–74.2%, and the variation is 2.8-fold. When interpreting the magnitude of variation, it is important to note: ›› the indicator does not include people who do not start treatment at all and/or who are not in touch with services; ›› some people who inject drugs are very mobile and may present to different services at different times. 22
  • 23. Hepatitis Although hepatitis C virus is a chronic infection, antiviral treatments are available that will successfully clear the virus in the majority of patients. However, unless there is a considerable increase in people receiving effective treatment, the future burden of hepatitis C-related disease will be substantial. Admission to hospital for hepatitis C and end-stage liver disease (ESLD) is an outcome indicator of how successful the identification and care of people with hepatitis C and its prevention have been. There is an 11 fold variation in the rate of hospital admissions for hepatitis C-related ESLD when the five PCTs with the highest rates and the five PCTs with the lowest rates are excluded. 23
  • 24. The Obesity Epidemic In England, there are potentially 1.4 million adults with fatty liver disease which may in some cases to lead to cirrhosis (non-alcoholic steatohepatitis) over the long term. We also estimate that there could be 60,000 10-year-olds with fatty liver. Extrapolating this for children aged 5–15 years, up to 500,000 children may already be at risk of developing an underlying liver disease that could lead to cirrhosis in the future. Obesity is closely related to the development of fatty liver disease, and 26% of the adult population, around 14.3 million people in England, is thought to be obese 24
  • 25. Obesity For PCTs in England, the percentage of children in school year 6 classified as overweight or obese ranged from 24.6% to 41.8% (1.7-fold variation). When the five PCTs with the highest percentages and the five PCTs with the lowest percentages are excluded, the range is 28.8–40.3%, and the variation is 1.4-fold. 25
  • 26. Obesity For PCTs in England, the percentage of estimated adult obesity ranged from 14.0% to 30.7% (2.2-fold variation). When the five PCTs with the highest estimated percentages and the five PCTs with the lowest estimated percentages are excluded, the range is 15.6–29.0%, and the variation is 1.9-fold. 26
  • 28. Cholecystectomy The degree of variation observed in total rates of cholecystectomy after exclusion is 2.4-fold whereas it is 8-fold for the percentage of elective adult day-case laparoscopic cholecystectomy per all elective cholecystectomies. If total rates of cholecystectomy are considered as a proxy for the burden of disease, it would appear that there is less variation in the burden of disease when compared with the variation in the type of care given. Further investigation is needed into the possible causes of lower rates of day-case surgery. If all providers in England were to match the day case performance of those in the upper quartile of day-case surgery rates for the BADS set of procedures, the estimated annual saving could release more than £64 million. 28
  • 29. Endoscopic Retrograde Cholangiopancreatography ERCP is a procedure in which an endoscope and X-rays are used to visualise the bile duct and the pancreatic duct. It can be used to diagnose or treat various conditions such as bile duct stones or pancreatic cancer. There should be no reason why the majority of patients undergoing the intervention as an elective procedure require an overnight stay. For PCTs in England, the variation is 28-fold. When the five PCTs with the highest percentages and the five PCTs with the lowest percentages are excluded, the variation is 13-fold. 29
  • 30. Endoscopic Retrograde Cholangiopancreatography The degree of variation observed in total rates of cholecystectomy after exclusion is 2.4-fold (see Map 31) whereas it is 8-fold for the percentage of elective adult day-case laparoscopic cholecystectomy per all elective cholecystectomies. The degree of variation observed in total rates of ERCP procedures after exclusion is 2.2-fold (see Map 33) whereas it is 13-fold for the percentage of elective ERCP procedures performed as day cases. If total rates of cholesystectomy and ERCP are considered as a proxy for the burden of disease, it would appear that there is less variation in the burden of disease when compared with the variation in the type of care given. Further investigation is needed into the possible causes of lower rates of day-case procedures. 30
  • 31. Reasons for variation The degree of variation observed in total rates of cholecystectomy after exclusion is 2.4-fold (see Map 31) whereas it is 8-fold for the percentage of elective adult day-case laparoscopic cholecystectomy per all elective cholecystectomies. The degree of variation observed in total rates of ERCP procedures after exclusion is 2.2-fold (see Map 33) whereas it is 13-fold for the percentage of elective ERCP procedures performed as day cases. If total rates of cholecystectomy and ERCP are considered as a proxy for the burden of disease, it would appear that there is less variation in the burden of disease when compared with the variation in the type of care given. Further investigation is needed into the possible causes of lower rates of day-case procedures. 31
  • 32. Innovations and models of good practice in services While working on the National Liver Disease Strategy, many models of good practice and some innovations likely to be helpful in tackling unwarranted variation were identified (Figure CS.1). They are presented in this Atlas as exemplars so that commissioners, clinicians and service providers can consider how they may be applied in their locality. 32
  • 33. Identifying liver disease earlier Risk assessment and early recognition of liver disease has been promoted by Liverpool PCT-CCG through the use of a locally enhanced service payment to minimise late diagnosis. Incentives are available to all participating primary care groups who: ›› identify patients at risk; ›› undertake relevant blood tests; ›› refer only those patients who meet the criteria for referral that have been agreed with local secondary care services – other patients are managed entirely in the community It was found that practices had different criteria and standards for referral within the PCT. Referral criteria and information standards were agreed with secondary care providers who agreed to provide a consultant-level opinion. Up to 40% of patients can be discharged with an advisory care plan at first consultation. 33
  • 34. Nottingham A variation of this type of service model was developed in Nottingham where all CCG referrals from individual practices were centralised at a single practice. A two-level triage system was used, in which a general practitioner with an interest in gastroenterology screened referrals. In cases where there was uncertainty, a brief synopsis of the case was emailed to 1 of 5 consultant hepatologists/gastroenterologists who screened the scenario and made clinical recommendations. Of a total of 354 potential referrals screened using this system during one year, 75% of hepatology referrals were dealt with by giving advice, blood tests, recommendations and appropriate community management plans. 34
  • 35. Alcohol abuse - Delivering brief interventions The introduction of alcohol liaison nurses has been recommended by the British Society of Gastroenterology and accepted by NHS Evidence as a QIPP example. In Nottingham, the introduction of an alcohol liaison nurse reduced readmission rates and drinking rates during a 12-month follow-up period. Similar models have proved effective in Bolton and Liverpool. In Salford, an extension of this process has been used to identify frequent attendees at A&E who are also known to other local authority agencies: a coordinated approach with key workers has decreased attendances and readmission rates. 35
  • 36. Triage of patients to secondary care… In Southampton, an algorithm was developed to triage patients to no fibrosis (green), cirrhosis (red), or an in-between group (amber) to whom interventions could be targeted to impede progression of scarring disease in the liver. Three tests were used - hyaluronic acid, collagen P3 peptide, and platelet count Ten thousand people in primary care were contacted by their own GPs and had their alcohol intake assessed: ›› just over 30% were assigned to the green category of risk of liver disease; ›› just over 40% were assigned to the amber category of risk of liver disease; ›› just under 30% were assigned to the red category of risk of liver disease. 36
  • 37. …Triage of patients to secondary care After assessment at one year, it was found that the initial categorisation was accurate with respect to not only the proportion of people assigned to each category of risk but also the severity of liver disease attributed to each individual. By identifying people in each category, preliminary results suggest that the higher the risk category identified, the greater is the impact of interventions aimed at reducing alcohol consumption in each group. This and other evidence points to the importance of individualising the information and risk assessment for people at risk of liver disease. 37
  • 38. Patient involvement: shared decision-making… Involvement of patients in the decision-making process leads to higher satisfaction, improved outcomes, greater knowledge of their condition and increased adherence to treatments. At University Hospitals Birmingham, patients were provided with the tools to engage in the decision making process, including access to their own health records, the ability to communicate with patients who have similar conditions and access to appropriate healthcare resources. A shadow hospital IT system was created that included the electronic prescribing and electronic outpatient note-keeping systems, so that patients could view their letters, appointments and blood-test results. As well as being able to access their health records, patients can also communicate with their healthcare team and learn about their long-term condition and its management. 38
  • 39. … Patient involvement: shared decision-making After successful feedback about the pilot, the system went live in July 2012 to patients being treated within the entire liver medicine specialty and also 10 other specialities within the Trust. After this initial rollout phase, there will be an external evaluation of the project. This is the first such project for patients with liver disease, although patients with kidney disease have experienced the benefits of a similar system, known as Renal PatientView4, for many years1. 1.http://www.renalpatientview.org 39
  • 40. www.rightcare.nhs.uk/atlas In print You can order free printed copies using the online form on our website Online High and Low resolution PDFs are available for download Interactive A fully interactive InstantAtlastm is available online 40
  • 41. Follow Right Care online: - Subscribe to get a weekly digest of our blog in your inbox - Receive Occasional eBulletins - Follow us on Twitter @qipprightcare www.rightcare.nhs.uk 41